Open-label extension study of vormatrigine in adults with epilepsy
Continues vormatrigine treatment in adults aged 18 to 85 with epilepsy.
Plain-language title generated from the registry record
Registry title: Clinical Trial of Vormatrigine in Adult Patients With Epilepsy
Key facts
- Where
- Bosisio Parini, Milan, Naples, Pavia, Pisa, Ponderano, Pozzilli, and Roma, ItalySee the 8 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT07287163, who can take part
Where in Italy
- Bosisio PariniBosisio Parini, ItalyNo longer taking part
- MilanMilan, ItalyNo longer taking part
- NaplesNaples, ItalyNo longer taking part
- PaviaPavia, ItalyNo longer taking part
- PisaPisa, ItalyNo longer taking part
- PonderanoPonderano, ItalyNo longer taking part
- PozzilliPozzilli, ItalyNo longer taking part
- RomaRoma, ItalyNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Praxis Precision Medicines
- Trial code
- NCT07287163
- Record updated
- 3 August 2026
- Original description
Open Label Extension Clinical Trial of Vormatrigine in Adult Patients with EpilepsyRead full original descriptionShow less
Open Label Extension Clinical Trial of Vormatrigine in Adult Patients With Epilepsy
Open Label Extension Clinical Trial of Vormatrigine in Adult Patients with Epilepsy
Inclusion: Participant who completed an eligible clinical trial (unless agreed by the sponsor medical monitor), including PRAX-628-212, PRAX-628-321 or other vormatrigine trials, or participant who has received vormatrigine outside of an eligible clinical trial (such as an expanded access program); Participant who had adequate seizure diary and vormatrigine adherence and had been otherwise adherent to the study procedures in the opinion of the investigator unless deemed unacceptable by sponsor.
Exclusion: Participant who plans to enter another interventional investigational study or is on any prohibited medication; Participant who withdrew or discontinued treatment from the treatment period of an eligible clinical trial unless deemed acceptable by the sponsor; Participant who is pregnant, lactating or planning to become pregnant; Participant who is ineligible for the extension clinical trial in the view of the investigator.